Lightcalls.com
 

CAs working for high-growth, mid-si...

CAs working for high-growth, mid-sized firms in BC know the value of a flexible financial partner committed to adding value beyond riches They also know the fundamental note factors to consider when selecting the best source of long-term capital for their businesses.

Key factors

* Knowledge of the business and sector:

A merchant bank, danger capital firm, or conventional lender that is unfamiliar with a business will find it more difficult to assess risk and will be les accommodating.

* boundarys and conditions: These move up or down the priority scale when the margin between financing proposals is thin or non-existent in bounds of cost.

* Appetite for further globulars of financing: Prudent financial managers want to know they can pass back to the well should additional capitals be required.

* Price of a loan or investment: This is especially conformable to fact of strong companies with the ability to store around.



* Breadth of financial services: What's in the financial partner's performance bag?

Seeing a deal from the point of view of those providing long-term capital strengthens a CFO's hand according to guiding them quickly to the right source of capitals and helping them negotiate the principally balanced capital structure and favourable seasons and conditions.

Here then is a merchant banker's perspective forward two hypothetical companies seeking long-term capital to firing material growth.

A mid-sized high-growth manufactures with stout cash flow and ample assets requires to finance an acquisition of another manufacturing firm with unhurt collateral

In this example, the decision between name debt, subordinated debt, and equity is straightforward. Because the company is financially stout debt instruments would take priority This firm's CFO should be looking for either a merchant bank or conventional lender willing and able to be flexible and add value.

While this company should talk with more than united capital source, companies-even strong ones-that call upon too many financial institutions risk being seen as "window shoppers" and not taken seriously.

This company's CFO should make an understanding of the business and relevant industry experience solution considerations. A merchant bank or lender that specializes in business financing in the company's sector would likely give more favourable terms and conditions and more carefully tailored capital manner of makings

The importance of a business plan to support this company's search can't be overemphasized. An effective business case presentation be attentive tos to negate irritating terms and conditions. Faith in management and the what is yet to be makes for greater flexibility.

Three competitive proposals are usually enough to establish a competitive price for currency However, slight differences in price should not be the principal reason for choosing common capital source over another. A difference of a quarter, or uniform of half a point, may not be as important as word s and conditions that could fetter management's flexibility.

Weigh all seasons and conditions, and beware of formula lender with strict, preset conditions. The repayment schedule, for example, should throw back seasonality, which affects cash grow performance and the normal life period of the assets being financed.

As for a commitment to add value, the flexibility of the capital edifice being offered and the space of times and conditions provide a clear signal. The CFO should also be stirred out their prospective financial partner's industry knowledge, additional services, and personal commitment to the to come success of the business, and weigh these factors before making a selection.

A high-growth, knowledge-based firm prosecutes an equity investment to acquire a company with proprietary technology nevertheless few assets

The difficulty many'-based companies have getting financing is well known. Typically, they don't have the collateral to branch the debt risk.

Therefore, the search in this case would be for an equity partner-either a merchant bank, luck capital fund, or angel that's comfortable with the company's sector, has demonstrated experience at working with of recent origin economy companies, and has a healthy appetite for coming investment.

A knowledge-based company's biggest assets are its senior management's knowledge and technical skills. When seeking equity, therefore, this hypothetical company's single in the greatest degree important priority would be to identify an equity partner with resources and contacts that's willing to levy its faith in management, the work and the marketplace.

As a knowledge-based company, the firm should talk with a number of capital sources, and management should arm itself with a well-crafted, easy-to-understand business plan to support negotiations. The plan should be kept simple and written in layman's language. Clarity is the key-not longitudinal dimensions or complexity.

Here's another tip: Prior to meeting a potential equity partner, it pays to rehearse the business case thoroughly. An outside consultant with knowledge of merchant banks, hap capital funds, and their respective policies, track records, and fruitss is often useful in this regard.



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.